Category Archives: ADC Technology

Home / ADC Technology
2 Posts

Clay Siegall, CEO and President of Seattle Genetics, is the main source behind the the generous donations into cancer research his organization has received. He is committed to fighting the threat of debilitating diseases and has spoken against the era that included chemotherapy as the only method to fight against cancer. His success lies behind his newly integrated ADCETICS antibody’s that are meant to separate killing cancer cells from killing normal cells because this has been the threat to many cancer patients. Siegall, understands their are unmet needs in cancer research and treatment and has been committed to effective strategies based on his clients needs.

He was once a value member of the big name GlaxoSmith-Kline pharmaceutical company and has been a part of his current co-founded Seattle Genetics organization for over 15+ years. His capital raising initiative has helped Seattle Genetics earn over 1.2 billion dollars for their research defense from public and private financial sources. There is a lot of family’s who suffer each year with a family member that is fighting cancer and have no choice, but to face chemotherapy when there are other options for treatment. Cancer patients no longer have to fight the threat of cancer on their own with integrated advanced medicine designed to save more lives and put cancer into complete remission for thousands of suffers.

You’re invited to learn more about Clay Siegall’s professional career by visiting his exclusive LinkedIn account or the Seattle Genetics website for more details. Be a part of the commitment by Seattle Genetics and Clay Siegall to fight against cancer with less chemotherapy.

Clay B. Siegall, Ph.D., is the cofounder, chief executive officer, and president of Seattle Genetics which was found in 1998. He is also the chairman of the board. His company is focused on targeted cancer therapies. He also built Seattle Genetics on a foundation of rigorous research, scientific innovation, drug development practices, and a passion in helping patients. Dr. Clay Siegall also guided his organization to it’s present leadership position in securing the 2011 FDA approval for ADCETRIS (brentuximab vedotin), the first ADC product. And now, ADCETRIS is under collaboration with Takeda Pharmaceutical Company, and this company is approved in over 65 countries.

There are other multiple strategic licenses that Seattle Genetics has entered for their ADC technology, including AbbVie, Pfizer, Genentech (Roche), and GlaxoSmithKline. And as a result, this company has generated over $350 million to date, and there are over 20 ADCs in clinical development across collaborator and internal programs by utilizing Seattle Genetics’ technology. And other Seattle Genetics has capital raising activities in which have secures over $1.2 billion through private and public financings which include the organization’s initial public offering in 2001.

Dr. Siegall’s Other Works

Before cofounding Seattle Genetics, Dr. Siegall worked for the Bristol-Myers Squibb Pharmaceutical Research Institute of Health from 1991 to 1997. From 1988 to 1991, he worked for the National Cancer Institute, National Institutes of Health. Dr. Siegall is on the board of directors for the Alder BioPharmaceuticals, Ultragenyx Pharmaceutical, and Washington Roundtable. He also has won several awards, including the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year, and the University of Maryland Alumnus of the Year for Computer, Math, and Natural Sciences in 2013. Dr. Siegall has also published over 70 publications, and he held 15 patents. And with his educational achievements, he earned a Ph.D. in Genetics from the George Washington University, and a B.S. degree in Zoology from the University of Maryland. Even with his WordPress blog, he has created several writings that are relatable to cell therapy and cancer. However, he also has written blogs, such as dreams, the flaws of science and undermining good medicine, and so forth.